The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer
The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer
复制标题
DOI：
10.1016/j.lungcan.2009.12.014
复制
发表时间：
2010-10-01
期刊：
影响因子：
5.3
通讯作者：
Haba, Reiji
中科院分区：
文献类型：
--
作者：
Kadota, Kyuichi;Huang, Cheng-Long;Haba, Reiji
背景：单克隆抗体 D2-40 已广泛用于人类癌症中的肿瘤淋巴管生成和淋巴管侵袭 (LVI)。然而，肿瘤细胞D2-40免疫反应性的临床意义尚未明确。患者和方法：我们评估了非小细胞肺癌（NSCLC）中的肿瘤细胞D2-40免疫反应性。对一百四十七名非小细胞肺癌患者进行了调查。使用 D2-40 进行免疫组织化学评估肿瘤细胞 D2-40 免疫反应性、微淋巴管密度 (Micro-LVD) 和 LVI。 CD34免疫染色评价瘤内微血管密度（MVD），Ki-67免疫染色评价肿瘤增殖情况。结果：鳞状细胞癌中D2-40阳性肿瘤细胞比例显着高于腺癌（P < 0.0001），且所有D2-40强的肿瘤均为鳞状细胞癌。中低分化肿瘤中D2-40强肿瘤的百分比显着高于高分化肿瘤（P=0.0332）。此外，D2-40强肿瘤中的Ki-67增殖指数显着最高。然而，肿瘤细胞 D2-40 免疫反应性与 Micro-LVD、LVI 或 MVD 无关。关于患者生存率，D2-40强肿瘤患者的总生存率显着低于D2-40阴性或D2-40弱肿瘤患者（P=0.0005）。多变量分析还显示肿瘤细胞D2-40免疫反应性是NSCLC患者预后不良的重要预后因素（P=0.0007）。结论：D2-40免疫染色可用于鉴别侵袭性肺鳞状细胞癌。 (C) 2009 Elsevier Ireland Ltd. 保留所有权利。
Background: A monoclonal antibody D2-40 has been widely used for tumor lymphangiogenesis and lymphatic vessel invasion (LVI) in human cancers. However, the clinical significance of the tumor cell D2-40 immunoreactivity has not been clearly understood.Patients and methods: We evaluated the tumor cell D2-40 immunoreactivity in non-small cell lung cancer (NSCLC). One hundred and forty-seven NSCLC patients were investigated. Immunohistochemistry using D2-40 was performed to evaluate the tumor cell D2-40 immunoreactivity, micro-lymphatic vessel density (Micro-LVD) and LVI. The intratumoral microvessels density (MVD) was evaluated by the CD34-immunostaining, and tumor proliferation was evaluated by the Ki-67-immunostaining.Results: The percentage of D2-40-positive tumor cells was significantly higher in squamous cell carcinomas than in adenocarcinomas (P < 0.0001), and all D2-40-strong tumors were squamous cell carcinomas. The percentage of D2-40-strong tumors was significantly higher in moderately to poorly differentiated tumors than in well-differentiated tumors (P=0.0332). Furthermore, the Ki-67 proliferation index in D2-40-strong tumors was significantly the highest. However, the tumor cell D2-40 immunoreactivity was not associated with Micro-LVD, LVI, or MVD. Regarding the patient survival, the overall survival was significantly lower in patients with D2-40-strong tumors than in patients with D2-40-negative or D2-40-weak tumors (P=0.0005). Multivariate analyses also revealed the tumor cell D2-40 immunoreactivity to be a significant prognostic factor of poor prognosis for NSCLC patients (P=0.0007).Conclusion: The D2-40 immunostaining is useful to identify aggressive squamous cell carcinomas of the lung. (C) 2009 Elsevier Ireland Ltd. All rights reserved.